Amylyx Pharmaceuticals (AMLX) EBIAT: 2021-2025
Historic EBIAT for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$34.4 million.
- Amylyx Pharmaceuticals' EBIAT rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 42.47%. This contributed to the annual value of -$301.7 million for FY2024, which is 712.42% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its EBIAT stood at -$34.4 million for Q3 2025, which was up 17.03% from -$41.4 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' EBIAT ranged from a high of $22.1 million in Q2 2023 and a low of -$118.8 million during Q1 2024.
- Its 3-year average for EBIAT is -$33.1 million, with a median of -$35.9 million in 2025.
- Per our database at Business Quant, Amylyx Pharmaceuticals' EBIAT soared by 140.83% in 2023 and then plummeted by 7,652.00% in 2024.
- Amylyx Pharmaceuticals' EBIAT (Quarterly) stood at -$28.3 million in 2021, then tumbled by 50.66% to -$42.7 million in 2022, then skyrocketed by 111.08% to $4.7 million in 2023, then slumped by 893.62% to -$37.5 million in 2024, then skyrocketed by 52.70% to -$34.4 million in 2025.
- Its EBIAT stands at -$34.4 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$35.9 million for Q1 2025.